Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

• Status: Terminated
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether bevacizumab can improve the outcome of treatment for patients with esophageal cancer whose disease is confined to the esophagus or the closely surrounding lymph nodes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Michigan Cancer Center; University of Michigan Rogel Cancer Center
• Collaborator: Genentech, Inc.
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Cisplatin; Fluorouracil; Paclitaxel

Criteria

Inclusion Criteria:

1. No prior treatment for esophageal cancer

2. No prior radiation to the chest or upper abdominal area

3. No prior treatment with an EGFR inhibitor or an anti-angiogenic agent

4. Disease should be limited to the esophagus and regional lymph nodes -

Exclusion Criteria:

1. History of stroke

2. History of heart attack

3. Inadequately controlled high blood pressure